Thomas S. Scanlan

15.4k citations

177 papers · 11.7k indexed · 2 hit papers · h-index 58

Impact in

Endocrinology, Diabetes and Metabolism top 0.1%
- Thyroid Disorders and Treatments
- Growth Hormone and Insulin-like Growth Factors
- Hormonal Regulation and Hypertension
Genetics top 0.2%
- Estrogen and related hormone effects

Papers in

Endocrinology, Diabetes and Metabolism 84
- Thyroid Disorders and Treatments 74
- Growth Hormone and Insulin-like Growth Factors 32
Genetics 53
- Estrogen and related hormone effects 44

Co-authors: Paul Webb Peter J. Kushner Stefan Nilsson George G. J. M. Kuiper Jan-Ακε Gustafsson John D. Baxter Robert J. Fletterick David K. Grandy
Journals: Endocrinology (22 papers)Journal of the American Chemical Society (10 papers)Journal of Biological Chemistry (6 papers)Journal of Medicinal Chemistry (6 papers)Proceedings of the National Academy of Sciences (5 papers)
Partner nations: United States Italy Brazil

In The Last Decade

Thomas S. Scanlan

173 papers receiving 11.4k citations

Hit Papers

align trajectories log scale

Estrogen receptor pathways to AP-1 2000 · 676 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2000 The Journal of Steroid Biochemistry and Molecular Biology
1997 Science

Peers

Countries citing papers authored by Thomas S. Scanlan

Since Specialization

Citations

This map shows the geographic impact of Thomas S. Scanlan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas S. Scanlan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas S. Scanlan more than expected).

Fields of papers citing papers by Thomas S. Scanlan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas S. Scanlan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas S. Scanlan. The network helps show where Thomas S. Scanlan may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Thomas S. Scanlan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas S. Scanlan Line = papers co-authored together Thomas S. Scanlan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Remyelination protects neurons from DLK-mediated neurodegeneration Nature Communications ·Greg J. Duncan, Xiaoyan Jin, Angelina Wright, Fradini Brillyandra, Christian Cordano, Ahmed Abdelhak, Matthew R. Balsor, Saloma Fn, Peng Xie, Mauricio Vasco, Skylar J. Ferrara, K. Filipsson, Benjamin Sivyer, Sue A. Aicher, Thomas S. Scanlan, Trent A. Watkins, Anusha Mishra, Jonathan W. Nelson, Ari Green, Ben Emery	2024	14
2	Maternal Administration of the CNS-Selective Sobetirome Prodrug Sob-AM2 Exerts Thyromimetic Effects in Murine MCT8-Deficient Fetuses Thyroid ·P. Vismara, Qiushi Duan, Thomas S. Scanlan, Soledad Bárez‐López, Ana Guadaño‐Ferraz	2023	7
3	Sobetirome prodrug esters with enhanced blood–brain barrier permeability Bioorganic & Medicinal Chemistry ·Andrew T. Placzek, Skylar J. Ferrara, Meredith D. Hartley, Stephen A. McKim, J. Matthew Meinig, Thomas S. Scanlan	2016	39
4	Tissue Distribution and Cardiac Metabolism of 3-Iodothyronamine Endocrinology ·Alessandro Saba, Grazia Chiellini, Sabina Frascarelli, Maja Marchini, Sandra Ghelardoni, Andrea Raffaelli, Massimo Tonacchera, Paolo Vitti, Thomas S. Scanlan, Riccardo Zucchi	2010	105
5	3-Iodothyronamine (T1AM): a new chapter of thyroid hormone endocrinology? Molecular BioSystems ·Alexandra G. Ianculescu, Thomas S. Scanlan	2010	25
6	Transport of thyroid hormones is selectively inhibited by 3-iodothyronamine Molecular BioSystems ·Alexandra G. Ianculescu, Edith C. H. Friesema, Theo J. Visser, Kathleen M. Giacomini, Thomas S. Scanlan	2010	22
7	Thyronamines: beyond T4 and T3 Thomas S. Scanlan	2010	1
8	Differential In Vivo Effects on Target Pathways of a Novel Arylpyrazole Glucocorticoid Receptor Modulator Compared with Prednisolone Journal of Pharmacology and Experimental Therapeutics ·Anni Juhlin, Krista A Varady, Scott Turner, Claire Emson, Richard W. Gelling, Mahalakshmi Shankaran, Glen Lindwall, Lauren E. Shipp, Thomas S. Scanlan, Jen-Chywan Wang, Marc K. Hellerstein	2010	11
9	Normal thermoregulatory responses to 3‐iodothyronamine, trace amines and amphetamine‐like psychostimulants in trace amine associated receptor 1 knockout mice Journal of Neuroscience Research ·Do Chil Lee, Vanessa Tui’one, Eric J. Vallender, Zhihua Xie, N. Fellowes, Spencer K. Lynn, Thomas S. Scanlan, Gregory M. Miller	2010	65
10	Stimulating the GPR30 Estrogen Receptor with a Novel Tamoxifen Analogue Activates SF-1 and Promotes Endometrial Cell Proliferation Cancer Research ·Benjamin C. Lin, Miyuki Suzawa, Raymond D. Blind, Sandra C. Tobias, Serdar E. Bulun, Thomas S. Scanlan, Holly A. Ingraham	2009	135
11	3-Iodothyronamine (T1AM): A New Player on the Thyroid Endocrine Team? Endocrinology ·Thomas S. Scanlan	2008	57
12	A role for 3-iodothyronamine in regulation of adipocyte lipolysis Wendy B. Closshey, Thomas S. Scanlan, Peter Taylor	2008	0
13	Iodothyronamines are Oxidatively Deaminated to Iodothyroacetic Acids in vivo ChemBioChem ·O. Tolu, Travis C. Geraci, Aaron Nilsen, Andrea E. DeBarber, Thomas S. Scanlan	2008	45
14	Thyroid hormone receptor subtype specificity for hormone-dependent neurogenesis in Xenopus laevis Developmental Biology ·Robert J. Denver, Fang Hu, Thomas S. Scanlan, J. David Furlow	2008	83
15	Selective Activation of Estrogen Receptor-β Transcriptional Pathways by an Herbal Extract Endocrinology ·Aleksandra Čvoro, Sreenivasan Paruthiyil, Jeremy O. Jones, Christina Tzagarakis-Foster, Nicola J. Clegg, Deirdre C. Tatomer, Laura Salmonsen, Mary Tagliaferri, Fred Schaufele, Thomas S. Scanlan, Marc I. Diamond, Isaac Cohen, Dale C. Leitman	2006	60
16	Unliganded thyroid hormone receptor is essential for Xenopus laevis eye development The EMBO Journal ·Emmanuelle Havis, Sébastien Le Mével, Ghislaine Morvan-Dubois, De‐Li Shi, Thomas S. Scanlan, Barbara A. Demeneix, Laurent M. Sachs	2006	59
17	Ligand-Selective Interactions of ER Detected in Living Cells by Fluorescence Resonance Energy Transfer Molecular Endocrinology ·Ross Weatherman, Ching‐yi Chang, Nicola J. Clegg, D. C. Carroll, Richard N. Day, John D. Baxter, Donald P. McDonnell, Thomas S. Scanlan, Fred Schaufele	2002	46
18	Albumin Regulates Induction of Peroxisome Proliferator-Activated Receptor-γ (PPARγ) by 15-Deoxy-Δ12–14-Prostaglandin J2 in Vitro and May Be an Important Regulator of PPARγ Function in Vivo*This work was supported by grants from the NSF (MCB-9513300; to E.C.P. and T.S.S.), the NIH [HD-08567 (to L.L.W.) and HD-30367 (to R.N.T.)], and the Sandler Foundation. Endocrinology* ·Dorothea Gough Rex, Leslie L. Waite, Robert N. Taylor, Thomas S. Scanlan	2001	15
19	Natural ligands of nuclear receptors have conserved volumes Nature Structural & Molecular Biology ·Andrew A. Bogan, Fred E. Cohen, Thomas S. Scanlan	1998	40
20	X-ray crystallographic and functional studies of thyroid hormone receptor The Journal of Steroid Biochemistry and Molecular Biology ·Ralff C.J. Ribeiro, James W. Apriletti, Richard Wagner, Weijun Feng, Peter J. Kushner, Stefan Nilsson, Thomas S. Scanlan, Brian L. West, Robert J. Fletterick, John D. Baxter	1998	59

About Thomas S. Scanlan

Thomas S. Scanlan is a scholar working on Endocrinology, Diabetes and Metabolism, Genetics, Developmental Neuroscience, Molecular Biology and Endocrine and Autonomic Systems, having authored 177 papers that have together received 11.7k indexed citations. Recurring topics across this work include Thyroid Disorders and Treatments (74 papers), Estrogen and related hormone effects (44 papers), Growth Hormone and Insulin-like Growth Factors (32 papers), Retinoids in leukemia and cellular processes (23 papers), Ion channel regulation and function (20 papers), Receptor Mechanisms and Signaling (16 papers), Monoclonal and Polyclonal Antibodies Research (14 papers) and Chemical Synthesis and Analysis (12 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (4.3k citations), Genetics (4.0k citations), Endocrine and Autonomic Systems (734 citations), Reproductive Medicine (784 citations) and Behavioral Neuroscience (307 citations). Thomas S. Scanlan has collaborated with scholars based in United States, Italy and Brazil. Frequent co-authors include Paul Webb, Peter J. Kushner, Stefan Nilsson, George G. J. M. Kuiper, Jan-Ακε Gustafsson, John D. Baxter, Robert J. Fletterick, David K. Grandy, Ngoc-Ha Nguyen and Grazia Chiellini. Their work appears in journals such as Endocrinology, Journal of the American Chemical Society, Journal of Biological Chemistry, Journal of Medicinal Chemistry and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact